SynthesisNeuromolecular medicine2014
The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease: a meta-analysis.
Synthesis in Neuromolecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Molecular Variants inInternational journal of women's health · 2025Article
- SIRT2 as a potential new therapeutic target for Alzheimer's disease.Neural regeneration research · 2024Review
- Blood Circulatory Level of Seven Sirtuins in Alzheimer's Disease: Potent Biomarker Based on Translational Research.Molecular neurobiology · 2022Article
- Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinson's disease.Scientific reports · 2021Article
- Review
- Correlation Between SIRT2 3'UTR Gene Polymorphism and the Susceptibility to Alzheimer's Disease.Journal of molecular neuroscience : MN · 2020Article
- Early sirtuin 2 inhibition prevents age-related cognitive decline in a senescence-accelerated mouse model.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- SIRT1 and SIRT2 Activity Control in Neurodegenerative Diseases.Frontiers in pharmacology · 2020Review
- Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics.International journal of molecular sciences · 2019Article
- Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.Acta neuropathologica · 2017Article
- A variant in SIRT2 gene 3'-UTR is associated with susceptibility to colorectal cancer.Oncotarget · 2017Article
- Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders.Neurochemical research · 2017Review
- Functional genetic variants within the SIRT2 gene promoter in acute myocardial infarction.PloS one · 2017Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have reported an association between human sirtuins' single-nucleotide polymorphisms (SNPs) and Alzheimer's disease (AD) susceptibility in the apolipoprotein E (APOE) ε4-negative population, although the findings are inconsistent. To obtain a more precise estimation of this relationship, we conducted a meta-analysis to assess the association between the rs10410544 C/T polymorphism of SIRT2 and the risk of AD with APOE ε4 status. We searched all relevant PubMed publications and included three studies in our meta-analysis involving a total of 1,794 patients and 2,054 control subjects. Odds ratios (ORs) with 95% confidence intervals (CIs) were employed to evaluate the association of the SIRT2 SNP with AD susceptibility, and we analyzed the extracted data stratified by the APOE ε4-carrying status. Overall, the results show that the SIRT2 SNP is associated with human AD risk in the comparison models (T vs. C: OR 1.140, 95% CI 1.034-1.258; TC vs. CC: OR 1.178, 95% CI 1.019-1.361; TT + TC vs. CC: OR 1.197, 95% CI 1.043-1.373). In the stratified analyses, the European population had a significantly increased risk of AD (T vs. C: OR 1.110, 95% CI 1.002-1.229), and we also observed a significant association in the APOE ε4-negative population (T vs. C: OR 1.165, 95% CI 1.025-1.324; TT + TC vs. CC: OR 1.222, 95% CI 1.022-1.461). This meta-analysis indicates that the presence of the SIRT2 SNP with APOE ε4-negative status contributes to the development of AD in humans Epidemiological studies of larger sample sizes are warranted to confirm this hypothesis.
Indexed as
Identifiers
24497179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.